Actively Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Led by Peking University People's Hospital · Updated on 2024-12-11
3000
Participants Needed
5
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a multicenter, prospective, longitudinal observational study to investigate thrombosis and hemostasis diseases in Chinese patients. These conditions include various bleeding and clotting disorders such as immune thrombocytopenia, thrombotic thrombocytopenic purpura, hemophilia, disseminated intravascular coagulation, thrombophilia, deep vein thrombosis, and pulmonary embolism. The study aims to analyze incidence, risk factors, treatment methods, prognosis, and medical expenses because current knowledge is limited by small sample sizes and lacks comprehensive large-scale data. This study collects patients' basic information, diagnostic and treatment details, and medical expense data from medical records. It uses questionnaires to assess patient exposures and follows patients prospectively to gather prognosis information over time. The study involves ongoing observation without any experimental treatment or intervention. Participants will have their medical records reviewed and complete questionnaires measuring exposure. Researchers will monitor outcomes such as prognosis over five years, incidence and distribution of diseases, treatment response, long-term remission rates, treatment safety, and health economic factors. The study includes follow-up assessments to gather comprehensive data on patient health and care costs, lasting up to five years.
CONDITIONS
Brief Title
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who were diagnosed as thrombosis and hemostasis diseases.
You will not qualify if you...
- Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
- Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.
- According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
/null
Duration - Up to 5 years
Participants are observed and data are collected on their thrombosis and hemostasis diseases, including treatment methods, prognosis, and medical expenses.
/null
Trial Site Locations
Total: 5 locations
1
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China, 100010
Actively Recruiting
2
Department of Hematology, Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Not Yet Recruiting
3
Department of Hematology, Beijing Hospital
Beijing, Beijing Municipality, China
Not Yet Recruiting
4
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Not Yet Recruiting
5
Xinqiao Hospital, Army Military Medical University
Chongqing, China
Not Yet Recruiting
Research Team
H
Haixia Fu, MD
Z
Zhuoyu An
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here